Kardigan, Inc. (NASDAQ:KARD – Get Free Report) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $41.00.
KARD has been the topic of a number of recent research reports. UBS Group started coverage on Kardigan in a research report on Monday, October 12th. They set a “buy” rating and a $25.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on Kardigan from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, August 25th. Cantor Fitzgerald began coverage on Kardigan in a report on Thursday, October 29th. They issued an “overweight” rating and a $50.00 price objective for the company. Weiss Ratings cut Kardigan from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, November 10th. Finally, HC Wainwright began coverage on shares of Kardigan in a report on Wednesday, November 4th. They set a “buy” rating and a $42.00 price objective on the stock.
Check Out Our Latest Report on Kardigan
Kardigan Trading Down 8.2%
Kardigan (NASDAQ:KARD – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.16. Equities analysts anticipate that Kardigan will post -3.39 earnings per share for the current year.
Institutional Trading of Kardigan
Several hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new position in Kardigan in the 3rd quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new position in Kardigan in the 3rd quarter valued at approximately $47,000. Legal & General Group Plc purchased a new position in Kardigan in the 2nd quarter valued at approximately $119,000. New York State Common Retirement Fund bought a new stake in Kardigan during the 3rd quarter valued at $145,000. Finally, Squarepoint Ops LLC bought a new stake in Kardigan during the 2nd quarter valued at $247,000.
About Kardigan
Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.
See Also
- Five stocks we like better than Kardigan
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Kardigan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kardigan and related companies with MarketBeat.com's FREE daily email newsletter.
